Table 3.

A description of treatments and outcomes in the individual cases. All catheter ablations performed were endocardial. A patient was deemed either a percutaneous stellate ganglion block (PSGB) responder or non-responder during our follow-up multidisciplinary electrophysiology meetings

Patient	Acute treatment	Sedation	PSGB responder	Long-term treatment	Outcome
1	Urgent PSGB	No	Yes	LCSD	Infrequent VA responsive to ATP recurred 15 months after LCSD. Deceased due to malignancy and worsening heart failure
2	Lidocaine	No	No	LCSD	No follow-up data available after transferral to a cardiac transplantation centre 2 weeks after LCSD
3	Amiodarone	No	Yes	Additional i.v. amiodarone	Free from VA after therapeutic amiodarone levels were achieved
4	Lidocaine	No	No	Catheter ablation	Urgent catheter ablation of a basal septal exit was performed after VA recurrence following PSGB. Deceased due to pneumonia
5	Amiodarone	Yes	Yes	LCSD	VA recurred following LCSD. Stabilised after two catheter ablations, both with extensive substrate modification
6	Urgent PSGB	No	No	LCSD	Deceased due to refractory VA 8 weeks after LCSD
7	Urgent PSGB	No	Yes	Catheter ablation	LCSD not feasible due to adhesions. Percutaneous radiofrequency stellate ganglion block was performed. After VT recurrence 6 weeks later referred to a university hospital
8	Amiodarone	Yes	Yes	Amiodarone i.v.	Free from VA
9	Sotalol and urgent PSGB	No	Yes	LCSD	Free from VA
10	Urgent PSGB	No	Yes	LCSD	Infrequent asymptomatic VT terminated by ATP recurred 6 months after LCSD
11	Sotalol and urgent PSGB	No	Yes	Amiodarone i.v.	Free from VA. Deceased due to pneumonia 2 years after LCSD
12	Amiodarone	No	No	Amiodarone i.v.	Deceased. Treatment discontinued after VT recurrence on day 2 after PSGB

VA ventricular arrhythmia, VT ventricular tachycardia, PSGB percutaneous stellate ganglion block, LCSD left cardiac sympathetic denervation, ATP antitachycardia pacing